ArticleTranslational breast cancer research : a journal focusing on translational research in breast cancer2026
Development of acute myeloid leukemia (AML) in two breast cancer patients undergoing treatment with long-term palbociclib: a dual case report.
Article in Translational breast cancer research : a journal focusing on translational research in breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute myeloid leukemia (AML) can develop after exposure to certain cytotoxic agents. Palbociclib, a cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor used to treat hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, is known for hematologic side effects but rarely associated with secondary hematologic malignancies. Case Description: We report two cases of AML development during prolonged breast cancer treatment with palbociclib, exploring a possible association. Case 1: a 63-year-old female diagnosed with stage I estrogen receptor (ER)/progesterone receptor (PR)-positive, HER2-negative breast cancer in 2010, treated with radiation and letrozole. Metastatic recurrence in 2019 prompted initiation of letrozole and palbociclib. In 2024, she developed anemia, neutrophilia, and circulating blasts, with bone marrow biopsy confirming AML. She was treated with azacitidine and venetoclax with poor response and died in 2025 from septic shock following surgery. Case 2: a 44-year-old female diagnosed with stage II hormone receptor-negative breast cancer in 1993, treated with surgery and chemotherapy. A local recurrence in 2005 was ER/PR-positive and she received letrozole until 2013. In 2017, she developed metastases and started letrozole and palbociclib. In 2025, she presented with pancytopenia and was diagnosed with AML. She received six cycles of azacitidine and venetoclax before progression and died later the same year. Conclusions: These cases explore a possible link between prolonged palbociclib therapy and AML development, warranting further investigation and monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.